Customize
Quick Links
Past Events

Accreditation/
Credit Designation

Physicians' Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians' Education Resource®, LLC, designates this live activity for a maximum of 3.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Acknowledgment of Commercial Support

This activity is supported by educational grants from Ablynx, a Sanofi Company, Apellis Pharmaceuticals, Dova Pharmaceuticals, Inc., Rigel Pharmaceuticals, Inc., and Sanofi Genzyme.

About
Accreditation
Privacy Policy
Terms & Conditions
Executive Board
Journal
Faculty Portal
Contact
Facebook
Twitter
LinkedIn
Google +
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 1-609-378-3701

Copyright © 2018
Physicians’ Education Resource ®, LLC.
All rights reserved.

ASH: “D” Is for Diagnosis”: Solving the Mystery of Rare Hematologic Disorders

ASH: “D” Is for Diagnosis”: Solving the Mystery of Rare Hematologic Disorders


Friday, November 30, 2018
1:30PM-4:30PM
Lunch and registration: 12:30 PM – 1:30 PM

Marriott Marquis San Diego Marina
Lunch: Grand Ballroom 1-4
Meeting Room: Grand Ballroom 1-4
333 W. Harbor Drive
San Diego, CA 92101

Overview:

Hematologists and primary care physicians play a pivotal role in the diagnosis and management of patients who present with hematologic symptoms of unknown origin. This program is designed to raise your awareness of rare hematologic disorders (ie, Gaucher’s disease, paroxysmal nocturnal hemoglobinuria, thrombotic thrombocytopenic purpura, and immune thrombocytopenia) and improve your ability to provide accurate and early diagnosis, as well as appropriate therapy for your patients with these conditions. The program will feature a mixed format of didactic lectures, panel discussions, and interactive clinical case studies. Throughout the case presentations, the program faculty of renowned experts in uncommon blood disorders will encourage you to seek clues from the clinical history and presentation, consider the differential diagnoses, and assess which tests are required to secure a definitive diagnosis. During the activity, the faculty will review the latest clinical data, share their best practices, review new and emerging strategies in the context of existing diagnostic and therapeutic algorithms, and offer opportunities for you to ask questions and share your own perspectives.

What you will learn about rare hematologic disorders:

  • Strategies to improve your differential diagnosis skills
  • Relevance of the pathophysiology and biology to the management of these disorders
  • State-of-the-art treatment approaches and treatment-related adverse event mitigation

Target Audience

These activities are intended for medical oncologists, hematologists, and other oncology healthcare professionals interested in understanding the current treatment guidelines and diagnostic strategies for patients who present with hematologic symptoms of unknown origin. Fellows, researchers, nurses, nurse practitioners, physician assistants, and other healthcare professionals are also invited to attend.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Illustrate the importance of rigorous differential diagnosis for patients with rare hematologic disorders
  • Detail pathophysiology of multiple rare diseases with hematologic implications and how underlying biology informs treatment decisions
  • Describe established evidence concerning treatment strategies to care for patients with thrombocytopenia or thrombosis resulting from rare blood disorders
  • Incorporate methods to proactively mitigate the impact of disease and treatment-related adverse events resulting from treating rare blood disorders

Acknowledgment of Commercial Support

This activity is supported by educational grants from Ablynx, a Sanofi Company, Apellis Pharmaceuticals, Dova Pharmaceuticals, Inc., Rigel Pharmaceuticals, Inc., and Sanofi Genzyme.

Activity Chair

Pramod K. Mistry, MD, PhD, FRCP, FAASLD
Professor of Medicine and Pediatrics
Professor of Cellular & Molecular Physiology
Department of Internal Medicine (Digestive Diseases)
Yale University School of Medicine
New Haven, CT







Become a Member

Forgot Password?
Filter By